Q4 2025 · 13F-HR
Merck & Co., Inc. (MRK)holdings as filed
Filed 2026-02-17 · accession 0000310158-26-000055
$276.3M
Reported value
12
Positions
2025-12-31
Period end
The Brief · Merck & Co., Inc. (MRK) · Q4 2025
AI · grounded in 13F
Merck & Co., Inc. (MRK) closed its position in Lava Therapeutics NV 4PKB, reducing its holdings by $1.79M. The fund also trimmed its stake in Sutro Biopharma Inc STRO by 90%. These moves were part of a broader reduction in two positions across a portfolio with $276.28M in total assets.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 71535D106 | PSNL | PERSONALIS INC | $111.8M | 40.5% | 14,044,943 | Common | SHARED |
| 60770K107 | MRNA | MODERNA INC | $68.1M | 24.6% | 2,308,190 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $60.1M | 21.7% | 772,165 | Common | SHARED |
| 29384C908 | TRDA | ENTRADA THERAPEUTICS INC | $17.9M | 6.47% | 1,739,768 | Common | SHARED |
| 29970R204 | EVAXUSD | EVAXION BIOTECH A/S | $5.8M | 2.10% | 1,214,126 | Common | SHARED |
| 014442107 | ALEC | ALECTOR INC | $5.5M | 2.00% | 3,545,719 | Common | SHARED |
| 869367102 | STRO | SUTRO BIOPHARMA INC | $3.2M | 1.14% | 272,351 | Common | SHARED |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $2.9M | 1.05% | 93,414 | Common | SHARED |
| 98422T100 | XLO | XILIO THERAPEUTICS INC | $949,902 | 0.34% | 1,483,758 | Common | SHARED |
| 14216R101 | CARM | CARISMA THERAPEUTICS INC | $63,349 | 0.02% | 1,473,240 | Common | SHARED |
| 64136E102 | NEUP | NEUPHORIA THERAPEUTICS INC | $38,905 | 0.01% | 10,027 | Common | SHARED |
| 898920103 | HURA | TUHURA BIOSCIENCES | $10,556 | 0.00% | 13,950 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.